Study with healthy volunteers to investigate the safety, tolerability, blood concentration and some effects of various amounts of the pharmaceutical substance SR-878

2023-507753-15-00 Protocol SR-878-01-001 Human pharmacology (Phase I) - Other Ended

Start 8 Oct 2024 · End 14 May 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol SR-878-01-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 52
Countries 1
Sites 1

Healthy Volunteers

Key facts

Sponsor
SciRhom GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
8 Oct 2024 → 14 May 2025
Decision date (initial)
2024-03-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-507753-15-00
WHO UTN
U1111-1296-7580

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy Volunteers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

SciRhom GmbH

Sponsor organisation
SciRhom GmbH
Address
Am Klopferspitz 19, Martinsried Martinsried
City
Planegg
Postcode
82152
Country
Germany

Scientific contact point

Organisation
SciRhom GmbH
Contact name
Scientific contact point

Public contact point

Organisation
SciRhom GmbH
Contact name
Scientific contact point

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Austria Ended 52 1
Rest of world 0

Investigational sites

Austria

1 site · Ended
Medical University Of Vienna
Department of Clinical Pharmacology, Waehringer Guertel 18-20, Alsergrund, Vienna

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Austria 2024-10-08 2024-10-08 2024-12-09

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-62704

Halt date
2024-12-09
Member states concerned
Austria
Publication date
2024-12-12
Reason
Safety related (clinical or pre-clinical results)
Explanation
The temporary halt is a recruitment stop. Participants who are in the study are subject to follow-up examinations according to the protocol.
Follow-up measures
Follow-up examinations according to the protocol.
Benefit-risk balance changed
Yes
Treatment stopped
Yes

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-08 Austria Acceptable with conditions
2024-03-04
2024-03-11
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-23 Austria Acceptable with conditions
2024-11-11
2024-11-18
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-11-29 Austria Acceptable with conditions
2024-11-11
2024-11-29